The Parker Institute for Cancer Immunotherapy is teaming with the Cancer Research Institute and 30 public and private entities — including biotech giant Genentech Inc., next-generation DNA sequencing startup Personalis Inc. of Menlo Park and the University of California, San Francisco – to detect so-called neoantigens that could point researchers toward specific cancer vaccines.
Sean Parker’s big push to hack cancer takes aim at tumor ‘tags’
My Health eNews
- Choose the news you want from more than two dozen topics.
- Medically-reviewed health news drawn from 350+ sources, delivered monthly to your inbox.
- Your username and password ensure your personalized news is delivered only to you.